Document Detail


Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function.
MedLine Citation:
PMID:  22800805     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
HYPOTHESES: Heart failure with preserved systolic function (HFPSF) has attained epidemic proportions; however evidence-based therapeutic interventions have not advanced despite continued research over the past three decades. We propose the combined use of direct renin inhibitor and carvedilol for this condition. RATIONALE: The Renin Angiotensin Aldosterone System (RAAS) plays a central role in myocyte hypertrophy, fibrosis and ventricular remodeling which is responsible for the diastolic dysfunction in HFPSF. Rising serum aldosterone levels with age have been implicated as a cause of myocardial fibrosis in the elderly. The sole use of Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers is associated with angiotensin-II and aldosterone escape and increased plasma renin activity. Carvedilol is a novel third generation non-selective β-blocker. The use of combination therapy will facilitate in better blood pressure control, reduce afterload, improve ventricular relaxation, cause regression of ventricular remodeling/fibrosis, maintain atrioventricular synchrony and enhance cardio-metabolic profile. The individual benefits of direct renin inhibitor and carvedilol could plausibly have a supra-additive effect when used in combination. Besides this, carvedilol can further reduce generation of free radicals, decrease LDL oxidation, improve Doppler echo diastolic parameters and decrease cardiac norepinephrine and density of cardiac β-receptors. CONCLUSION: Evidence suggests that patients with HFPSF are treated less aggressively as compared to patients with heart failure with systolic dysfunction. Aggressive therapy with concurrent use of direct renin inhibitor and carvedilol will help in improving outcomes in this vulnerable patient sub-population. No prior trial has evaluated the combined use of these drugs for the treatment of HFPSF.
Authors:
Apurva O Badheka; Tushar Anil Tuliani; Ankit Rathod; Mohammad Ali Kizilbash; Aditya Bharadwaj; Luis Afonso
Related Documents :
21874245 - Cyclooxygenase mediates cardioprotection of angiotensin-(1-7) against ischemia/reperfus...
10948775 - Quantification of right and left ventricular function by cardiovascular magnetic resona...
674685 - Natural history of obstructive coronary artery disease: ten-year study of 601 nonsurgic...
22829055 - Dietary chitosan supplementation attenuates isoprenaline-induced oxidative stress in ra...
2720925 - Left ventricular contractility and function in kawasaki syndrome. effect of intravenous...
16204745 - The mayo clinic risk score predicts in-hospital mortality following primary angioplasty.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-14
Journal Detail:
Title:  Medical hypotheses     Volume:  -     ISSN:  1532-2777     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7505668     Medline TA:  Med Hypotheses     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Ltd.
Affiliation:
Wayne State University, Detroit Medical Center, Internal Medicine, Division of Cardiology, 8 Brush, Harper University Hospital, 3990 John R. Street, Detroit, MI 48201, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polyunsaturated fatty acids as putative cognitive enhancers.
Next Document:  Characterization of Nociceptive Responses to Bee Venom-induced Inflammation in Neonatal Rats.